JP2023550626A - ＴＧＦ－βポリペプチド - Google Patents

ＴＧＦ－βポリペプチド Download PDF

Info

Publication number
JP2023550626A
JP2023550626A JP2023530765A JP2023530765A JP2023550626A JP 2023550626 A JP2023550626 A JP 2023550626A JP 2023530765 A JP2023530765 A JP 2023530765A JP 2023530765 A JP2023530765 A JP 2023530765A JP 2023550626 A JP2023550626 A JP 2023550626A
Authority
JP
Japan
Prior art keywords
polypeptide
tgf
sequence
seq
polypeptide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023530765A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550626A5 (enExample
Inventor
ディー． セイデル ザ サード ロナルド
ジェイ． チャパルロ ロドルフォ
エフ． ロス ジョン
メング ロー チー
スリ アニッシュ
ジャコモ レヴィセッティ マテオ
Original Assignee
キュー バイオファーマ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キュー バイオファーマ，インコーポレーテッド filed Critical キュー バイオファーマ，インコーポレーテッド
Publication of JP2023550626A publication Critical patent/JP2023550626A/ja
Publication of JP2023550626A5 publication Critical patent/JP2023550626A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023530765A 2020-11-23 2021-11-22 ＴＧＦ－βポリペプチド Pending JP2023550626A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063117307P 2020-11-23 2020-11-23
US63/117,307 2020-11-23
US202163177935P 2021-04-21 2021-04-21
US63/177,935 2021-04-21
US202163195673P 2021-06-01 2021-06-01
US63/195,673 2021-06-01
US202163250990P 2021-09-30 2021-09-30
US63/250,990 2021-09-30
PCT/US2021/060357 WO2022109399A1 (en) 2020-11-23 2021-11-22 Tgf-beta polypeptides

Publications (2)

Publication Number Publication Date
JP2023550626A true JP2023550626A (ja) 2023-12-04
JP2023550626A5 JP2023550626A5 (enExample) 2025-01-07

Family

ID=81709765

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023530765A Pending JP2023550626A (ja) 2020-11-23 2021-11-22 ＴＧＦ－βポリペプチド

Country Status (5)

Country Link
US (1) US20230416321A1 (enExample)
EP (1) EP4247431A4 (enExample)
JP (1) JP2023550626A (enExample)
CA (1) CA3174130A1 (enExample)
WO (1) WO2022109399A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250151519A (ko) * 2023-02-20 2025-10-21 아케소 바이오파마 컴퍼니 리미티드 TGF-βRII 세포 외 영역 단편을 포함하는 융합 단백질, 및 이의 약제학적 조성물, 및 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012520059A (ja) * 2009-02-23 2012-09-06 サイトムエックス セラピューティクス， インコーポレイテッド プロタンパク質およびその使用方法
WO2020069398A1 (en) * 2018-09-27 2020-04-02 Akrevia Therapeutics Inc. Masked cytokine polypeptides
JP2020518246A (ja) * 2017-05-04 2020-06-25 アクセルロン ファーマ， インコーポレイテッド Ｔｇｆベータ受容体ｉｉ型融合タンパク質およびその使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110165623A1 (en) * 2004-01-06 2011-07-07 The Government Of The U.S. As Represented By The Secretary, Dept. Of Health & Human Services Compositions and Methods for the High Efficiency Expression of the Transforming Growth Factor-Beta Supergene Family
JP5841845B2 (ja) * 2009-02-24 2016-01-13 ソーク・インステチュート・フォー・バイオロジカル・スタディーズＳａｌｋ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｌｏｇｉｃａｌ Ｓｔｕｄｉｅｓ ＴＧＦ−βスーパーファミリーのデザイナーリガンド

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012520059A (ja) * 2009-02-23 2012-09-06 サイトムエックス セラピューティクス， インコーポレイテッド プロタンパク質およびその使用方法
JP2020518246A (ja) * 2017-05-04 2020-06-25 アクセルロン ファーマ， インコーポレイテッド Ｔｇｆベータ受容体ｉｉ型融合タンパク質およびその使用
WO2020069398A1 (en) * 2018-09-27 2020-04-02 Akrevia Therapeutics Inc. Masked cytokine polypeptides

Also Published As

Publication number Publication date
EP4247431A1 (en) 2023-09-27
EP4247431A4 (en) 2024-11-27
US20230416321A1 (en) 2023-12-28
CA3174130A1 (en) 2022-05-27
WO2022109399A1 (en) 2022-05-27

Similar Documents

Publication Publication Date Title
US11692018B2 (en) TGF-β polypeptides
US20210047382A1 (en) Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
CN113286609B (zh) 多聚体t细胞调节多肽及其使用方法
JP2022046544A (ja) ｓｙｎＴａｃポリペプチド及びその使用
JP2022544771A (ja) 優先的にｉｌ－２ｒアルファに結合するｉｌ－２融合タンパク質
KR20230009872A (ko) 다량체 t-세포 조절 폴리펩타이드 및 이의 사용 방법
US20240190933A1 (en) Antigen Presenting Polypeptide Complexes Bearing TGF-Beta and Methods of Use Thereof
JP2024533848A (ja) 炎症組織へのターゲティング特異性を備えるインターロイキン２キメラコンストラクト
JP2023550626A (ja) ＴＧＦ－βポリペプチド
US7557084B2 (en) IL-18 specific polypeptides and therapeutic uses thereof
US20250236653A1 (en) Targeted low potency il-12 fc fusion proteins and uses thereof
CN116096405B (zh) 多聚体t细胞调节多肽及其使用方法
TW202502807A (zh) 融合il10多肽
KR20230009391A (ko) 다량체 t-세포 조절 폴리펩타이드 및 이의 사용 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260203